Skip to main content

The Hidden Hazard of Pacemakers: Pacing Lead-Induced Tricuspid Regurgitation

A 65-year-old man with a history of complete heart block underwent pacemaker implantation. A few months later, he presented with symptoms of fatigue and shortness of breath. An echocardiogram was performed, which showed significant tricuspid regurgitation. The video below shows the echocardiogram images, which clearly demonstrate the pacing lead interfering with the tricuspid valve and causing regurgitation.


Browse FREE ECHO LIBRARY>>

As shown in the video, the pacing lead is seen to be interfering with the normal coaptation of the tricuspid valve leaflets, leading to significant regurgitation. This is a classic example of pacing lead-induced tricuspid regurgitation. The patient's symptoms were attributed to the regurgitation, and he underwent lead repositioning, which resolved the issue.

Pacing lead-induced tricuspid regurgitation is a complication that can arise in patients with permanent pacemakers. It occurs when the pacing lead, which is inserted through a vein and guided to the heart, interferes with the normal functioning of the tricuspid valve. This can lead to regurgitation, or the leakage of blood, through the valve.


The tricuspid valve is a critical structure in the heart that separates the right atrium and right ventricle. It is designed to allow blood to flow from the right atrium into the right ventricle while preventing blood from flowing backward. However, when a pacing lead is inserted, it can sometimes interfere with the valve's function, causing it to leak. This can lead to symptoms such as fatigue, shortness of breath, and swelling in the legs and feet.


Pacing lead-induced tricuspid regurgitation is a relatively rare complication, but it is an important one to recognize. It can be diagnosed using echocardiography, which provides valuable information about the valve's function and the lead's position. Treatment options include lead repositioning, lead extraction, or valve repair or replacement in severe cases.


In conclusion, pacing lead-induced tricuspid regurgitation is a potential complication of pacemaker implantation. It is essential to recognize the signs and symptoms of this condition and to use echocardiography to diagnose it. With prompt treatment, patients can experience significant improvement in their symptoms and quality of life.


Browse FREE ECHO LIBRARY>>


Comments

Popular posts from this blog

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.

2025 ESC Guidelines on INR Targets in Mechanical Valves

  2025 ESC Guidelines on INR Targets in Mechanical Valves INR Targets in Patients With Mechanical Heart Valves Updated, guideline-oriented review Mechanical heart valves are inherently thrombogenic and require lifelong anticoagulation. Vitamin K antagonists, particularly warfarin, remain the standard therapy. The international normalized ratio (INR) is used to guide anticoagulation intensity and must be individualized based on valve type, valve position, and patient-related thromboembolic risk factors. Subtherapeutic INR increases the risk of valve thrombosis and systemic embolism, whereas excessive anticoagulation increases bleeding risk. Why INR control is critical Mechanical valves promote thrombosis due to non-physiological blood flow, high shear stress, and continuous contact between blood and artificial surfaces. These prothrombotic mechanisms persist for life. Direct oral anticoagulants are contraindicated in mechanical valves; therefore, VKAs remain mandatory. The goal of I...